<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249130</url>
  </required_header>
  <id_info>
    <org_study_id>1182.3</org_study_id>
    <nct_id>NCT02249130</nct_id>
  </id_info>
  <brief_title>Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir</brief_title>
  <official_title>Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the safety of a standard triple therapy regimen of delavirdine (DLV),
      zidovudine (ZDV), and lamivudine (3TC) following 14 days of experimental treatment with
      regimens of tipranavir (TPV) with and without ritonavir (RTV)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>Up to 46 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with drug-related adverse events</measure>
    <time_frame>Up to 46 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with AIDS clinical trials group (ACTG) grade 3 or 4 toxicity</measure>
    <time_frame>Up to 46 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a treatment toxicity leading to study discontinuation</measure>
    <time_frame>Up to 46 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with serious treatment-emergent adverse events</measure>
    <time_frame>Up to 46 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in laboratory parameters</measure>
    <time_frame>Up to 46 weeks</time_frame>
    <description>Only lab values associated with metabolic disorders</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir (TPV)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (RTV)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine (DLV)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (ZDV)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine (3TC)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine (d4T)</intervention_name>
    <arm_group_label>Treatment of HIV- infected patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 RNA ≥ 5,000 copies/mL by Roche Amplicor assay

          -  CD4 cell count ≥ 50 cells/mm3

          -  Karnofsky performance status ≥ 80

          -  Age ≥ 13 years

          -  Screening laboratory values indicative of adequate baseline organ function, Grade 0 or
             1 for laboratory values based on the ACTG toxicity scale grade. Selected stable [2
             months or longer] Grade 2 laboratory abnormalities were subject to sponsor's approval

          -  Acceptable medical history and physical examination

          -  Agreement to use a barrier contraceptive method for at least 1 month prior to the
             administration of the study medication, during the study, and for 30 days after the
             end of the study

          -  Signed informed consent

          -  To enter the post-study option, patients have to have completed the 14-day tipranavir
             phase of the trial

        Exclusion Criteria:

          -  Previous treatment with any antiretroviral drugs for more than 2 weeks

          -  Clinically significant, active and/or acute (onset within the prior month) medical
             problems including opportunistic infections, such as active cryptococcosis,
             Pneumocystis carinii pneumonia (PCP), herpes zoster, histoplasmosis or cytomegalovirus
             (CMV) , or non-opportunistic diseases including, but not limited to, progressive
             multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy

          -  History of clinically significant nervous system or muscle diseases, seizure disorder,
             or psychiatric disorder that might impair compliance with the study

          -  Receipt of any known enzyme-inducing drugs including rifabutin, rifampin,
             carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfamidine, sulfinpyrazone,
             or troleandomycin within 30 days prior to participation in the study

          -  Receipt of any investigational medication within 30 days prior to participation in the
             study

          -  Receipt of oral contraceptives within 30 days prior to participation in the study

          -  Pregnancy or lactation (serum ß-human chorionic gonadotropin (ß-HCG) test negative at
             second screen visit of the tipranavir phase of trial)

          -  Evidence of active substance abuse that, in the investigator's opinion, could affect
             study adherence

          -  In the investigator's judgment, inability to comply with the protocol requirements for
             reasons other than those specified above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

